Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 12, 2010
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled studyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
Journal of Virology|July 14, 2017
HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIVVijaya Madhavi, Bruce D Wines, Janaki Amin, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
The Journal of Infectious Diseases|October 15, 2010
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa, Andrew Ratsela, Michael Polis, et al.
AIDS (London, England)|January 26, 2017
Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infectionAlan R Lifson, Birgit Grund, Edward M Gardner, et al.
Clinical Trials (London, England)|May 2, 2012
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) studyAbdel G Babiker, Sean Emery, Gerd Fätkenheuer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2010
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair studyRebekah L Puls, Preeyaporn Srasuebkul, Kathy Petoumenos, et al.
Antiviral Therapy|April 28, 2017
Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trialAmanda H Yao, Cecilia L Moore, Poh Lian Lim, et al.
AIDS (London, England)|March 14, 2012
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwardsJohn M Murray, Kristin McBride, Christoph Boesecke, et al.
AIDS (London, England)|August 24, 2011
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoirKersten K Koelsch, Christoph Boesecke, Kristin McBride, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 12, 2010
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled studyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
Journal of Virology|July 14, 2017
HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIVVijaya Madhavi, Bruce D Wines, Janaki Amin, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
The Journal of Infectious Diseases|October 15, 2010
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa, Andrew Ratsela, Michael Polis, et al.
AIDS (London, England)|January 26, 2017
Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infectionAlan R Lifson, Birgit Grund, Edward M Gardner, et al.
Clinical Trials (London, England)|May 2, 2012
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) studyAbdel G Babiker, Sean Emery, Gerd Fätkenheuer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2010
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair studyRebekah L Puls, Preeyaporn Srasuebkul, Kathy Petoumenos, et al.
Antiviral Therapy|April 28, 2017
Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trialAmanda H Yao, Cecilia L Moore, Poh Lian Lim, et al.
AIDS (London, England)|March 14, 2012
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwardsJohn M Murray, Kristin McBride, Christoph Boesecke, et al.
AIDS (London, England)|August 24, 2011
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoirKersten K Koelsch, Christoph Boesecke, Kristin McBride, et al.
Pageof 14